Scale (KPS), Spitzer QOL-Index, Expanded Disability Status Scale (EDSS), and the Hamilton Rating Scale for Depression (HAM-D) were evaluated in terms of: conceptual framework; patient, literature and clinician contribution to development; process for deriving items; content validity; item reduction; linguistic and cultural adaptation; scoring; and reliability, validity, and ability to detect change. RESULTS: The FDA discourages the use of CROs for symptoms that can only be known to the patient, whereas clinical signs are usually observed and interpreted by the clinician. Despite the widespread use of the KPS as a classification of functional status in patients with cancer, there is little data supporting the development, content validity, and statistical measurement properties of the scale. Among other critiques, the EDSS has questionable inter-rater reliability. Although the Spitzer QOL-index was developed with patient input and has documented measurement properties, the use of proxy for QOL/ HRQL evaluations is widely discouraged. The HAM-D is considered the 'gold standard' of depression rating scales with good psychometric properties, but with questionable content validity. CONCLUSIONS: The suitability of the selected CROs as endpoints for regulatory approvals varied widely. CROs are essential and complimentary primary and secondary endpoints for drug evaluations for the purpose of FDA regulatory submissions, it is likely that sponsors will face increasing FDA scrutiny of CRO endpoints for the purpose of label claims.
PMC3

REVIEW OF COST EFFECTIVENESS ANALYSES THAT INCORPORATE NUMBER NEEDED TO TREAT/HARM VALUES
Raisch DW, Nawarskas JJ University of New Mexico College of Pharmacy, Albuquerque, NM, USA INTRODUCTION: Number needed to treat/harm (NNT/NNH) values are universally understood and applied by clinical decision makers. Therefore providing these values alongside cost effectiveness analysis (CEA) results may increase the relevance and clarify clinical implications of CEAs to decision makers. OBJECTIVES: To review the literature of CEA studies that incorporate NNT/NNH values. METHODS: We searched Pub Med using the Mesh term "cost-benefit analysis" and "number needed to treat ", "number needed to harm", "NNT", or "NNH". We included CEA studies and studies describing relationships between NNT/NNH and quality adjusted life years (QALYs) published in English. RESULTS: There were 102 publications identified. Of these 47 provided both CEA and NNT/NNH results. There were 43 (91.5%) studies published in clinician-focused practice journals, 2 (4.3%) in policy journals, and 2 (4.3%) in economic journals. The CEA incorporated NNT/NNH directly as part of the CEA ratio in 23 (48.9%) studies and CEA was separately stated from NNT/NNH in 14 (29.8%) studies. The CEA was expressed as cost per QALY distinctly from NNT/NNH in 10 (21.3%). The focuses of the articles were disease treatments in 28 (59.5%) studies, disease prevention in 15 (31.9%), and patient education or disease management in 2 (4.3%) each. Also, there were 4 studies regarding relationships between NNT/NNH and QALYs. CONCLUSIONS: We found that the majority of articles incorporating NNT/NNH into CEA were published in clinical practice journals and most involved comparisons of specific disease treatments. Incorporating NNT/NNH into CEA results may improve relevance to clinical decisionmaking, but further research is needed regarding how they are best integrated. One alternative may include weighting NNT/NNH values for different outcomes in terms of QALYs.
PMC4 THE DERIVATION OF TRICARE SPECIFIC CONSUMER PRICE INDICES FOR PRESCRIPTION DRUGS
Summers CR TRICARE Management Activity, Falls Church, VA, USA OBJECTIVES: One of the chronic issues in pharmaceutical utilization management is the dearth of accurate price benchmarks available to establish pharmacy-pricing performance. This paucity of appropriate benchmarks is further complicated for organizations, such as TRICARE, who have reason to believe that their demographics and hence disease profiles yield atypical prescription drug market baskets. Thus, to obtain an accurate assessment of organizational performance, organization-specific indices need to be developed. METHODS: A unique approach to developing organization specific benchmarks is underway in a joint venture between the TRICARE Pharmaceutical Operations Directorate (POD) and the US Bureau of Labor Statistics (BLS). The primary method is to match retail pricing information provided by BLS and portfolio information provided by TRICARE to construct organization specific benchmarks that can be tracked over time. Variables from the Consumer Price Index for Prescription Drugs (CPI-Rx) are transferred to the POD as specified in an intergovernmental memorandum of understanding. To form an overall TRICARE-Rx index for a specific month, all TRICARE prescription data are aggregated by specific drug and the number of prescriptions is computed for each drug for specific month using a file extracted from the Pharmacy Data Transaction Service (PDTS). CPI-Rx prices are then aggregated by same list of unique drugs used in the TRICARE sample then averaged in a separate file. The files are then merged using NDC codes as the key. The index is computed using the average CPI-Rx price for each specific drug multiplied by the TRICARE N for the corresponding drugs then averaged. CONCLU-SIONS: TRICARE spends roughly $7.5 Billion annually for prescription drugs. With the development of these indices, we can better gauge our cost containment priorities and efforts. This will help us determine if increases in costs are due to general drug price inflation specific to our unique market basket of drugs.
PMC5 VALIDATING A WEB-BASED INCREMENTAL COST-EFFECTIVENESS SOFTWARE PROGRAM THAT USES A MARKOV TRANSITION PROBABILITY MATRIX ANALYSIS MODEL
McGhan W, Zaveri V, Willey VJ, Gohil N University of the Sciences in Philadelphia, Philadelphia, PA, USA OBJECTIVES: Commercial software can be expensive when conducting pharmacoeconomic analyses. We developed a free web-based software program, which incorporates Markov transition probabilities to compare the cost-effectiveness of any two treatments. The web-based software program was based on the model described in a decision modeling for health economic evaluation textbook, edited by A. Briggs. This Markov web-based software program calculates the incremental cost-effectiveness based on Markov matrices using multi-state transition probabilities, along with corresponding Markov state costs and utilities and graphically displays the results, using JavaScript algorithms and is available free at www.healthstrategy.com. The variable inputs for two treatment options include state transition probabilities, number of cycles, cost per state, and utility per state. The software creates a plot of incremental costs versus incremental utilities in cost-effectiveness quadrants; and with death as an absorbing state, also graphs life expectancy curves for two treatment comparisons. The objective of this study was to validate this free web-based software. METHODS: The Excel spreadsheet structure and data downloaded from the web for the specific example described in the modeling textbook were used as the reference case. RESULTS: For the example used, considering four transition states for each therapy option, and 20 cycles with no discounting, the MS Excel spreadsheet model versus the web-based JavaScript software compared as follows: average incremental US dollar costs: ($67701 vs. $67853), average incremental utility: (5.89 vs. 5.90) and average incremental cost-effectiveness ratio:($11500 vs. $11494). CONCLUSIONS: This free web-based Markov matrix JavaScript program gives similar results as the MS Excel spreadsheet model. With this free software, the user can input their own therapy parameters, and generate incremental costs, incremental utilities, life expectancy curves, and incremental cost effectiveness ratios. This free web-based software has potential benefit as an educational tool for students and health professionals interested in exploring these analytical approaches.
PMC6 USE OF CLINICAL SIMULATION CENTERS TO CONDUCT PATIENT-CENTERED TIME-AND-MOTION SIMULATIONS AS A BASIS FOR ECONOMIC ANALYSIS
Nickman N, Haak S, Kim J University of Utah, Salt Lake City, UT, USA BACKGROUND: Patient-centered professional practice and technology assessment research performed in health professional schools' clinical simulation centers is a novel concept. Opportunities can be created for multidisciplinary collaboration relative to evaluation of medication regimen and device complexity. Micro-level costs can then be assigned and economic analysis conducted in a more precise fashion than in traditional clinical trials or database outcomes analysis. METHODS: One university's pharmacy and nursing schools' clinical simulation centers were used in two separate projects to conduct time-and-motion and activity-based costing analyses specific to work-related activities consisting of nurse, pharmacist, and/or patient medication dispensing, preparation, administration and/or storage. Projects consisted of time and cost differences related to 1) three proton pump inhibitor dosage forms and seven administration methods, and 2) seven recombinant human growth hormone administration methods/devices. Performance-based time data were then used to determine personnel/patient opportunity time and supply costs associated with different forms of medications and delivery devices. Simulations were developed and used to hold independent variables constant so only observed differences between medications and/ or device types could be assessed. Statistical and micro-economic cost analyses were conducted specific to each type of medication and/or device. RESULTS: Processes and results show two detailed examples as case studies of how simulation-based research may be used to assess health care processes at the micro level. The advantages of isolating processes of interest from the day-to-day complexity of patient care are demonstrated. Simulations may also represent an efficient assessment alternative of health care processes at the micro level with potential for projection to the macro level as compared to live, direct observation, cost-intensive, patient-centered care practice evaluations. CONCLUSIONS: Simulation-based time-and-motion and activity-based cost analyses allowed detailed micro-level time, workload, and supply evaluations that may be projected to the macro level. Professional schools' simulation laboratories offer appropriate settings for such studies.
PMC7 ESTIMATING TIME-PROFILED ECONOMIC BURDEN OF ILLNESS
Cao Z 1 , Song X 1 , Mark T 2 1 Thomson Reuters, Cambridge, MA, USA, 2 Thomson Reuters, Washington, DC, USA OBJECTIVES: Demonstrate a technique to characterize the economic burden of illness over time, correcting for censoring bias and controlling for difference in baseline characteristics between comparison groups. A sample of patients with diagnosis of disease A in 2004-2008 were extracted from MarketScan® databases and followed to death, disenrollment, or December 31, 2008 (cases). The first diagnosis date was the index date. Enrollees without disease A were extracted as controls. Their index dates were assigned based on the distribution of index dates of cases. METHODS: First, Kaplan-Meier estimates for the probability of remaining in the data were calculated by month and disease status. Failure event was death or disenrollment. Censoring event was termination of MarketScan contract or end of study period. Next, total health care costs were estimated using generalized linear models (GLM) on the subsample of survivors/enrollees in each month, controlling for disease status, patient demographic and clinical characteristics. Adjusted costs were calculated by month and disease status using the regression estimates and average characteristics. Estimated total costs during the whole follow-up period were the sum of probability of remaining in the data multiplied by regression-adjusted costs in each month. RESULTS: At the end of year 1, 40.5% of cases deceased or disenrolled from insurance compared to 13.6% of controls (p < 0.001); at the end of year 4 these figures were 76.4% and 30.5%, respectively (p < 0.001). GLM results indicated significantly higher cost among the group with disease A in each month during follow-up. The adjusted costs based on average characteristics was $86,592 for cases vs. $6,178 for controls in the first year and $151,077 vs. $21,890 in the first 4 years. CONCLUSIONS: In studies with variable-length follow-up, an estimator combining the survivor probability and regression-adjusted cost is more robust to censoring bias, and better depicts the economic burden of illness over time.
CONCEPTUAL PAPERS & RESEARCH ON METHODS -Databases & Management Methods
PMC8 THE EFFECT OF LENGTH OF OBSERVATION AND CLAIMS DATA TYPE ON ESTIMATES OF COMORBIDITIES AMONG MEDICAID BENEFICIARIES
Banahan III BF, Pace PF University of Mississippi, Oxford, MS, USA OBJECTIVES: Researchers frequently use claims data to create comorbidity measures. The objective of this project was to examine how the number of months of observation data and the type of claims data can affect identification of comorbidities. METHODS: Inpatient (IP) and outpatient (OT) claims data were used to identify comorbidities for beneficiaries enrolled in a state Medicaid program. Beneficiaries were included if they were enrolled for a continuous 24-month period between January 2002 and December 2004. Data were used to identify the first month in which an ICD-9 code appeared for each of the 17 comorbidities included in the Charlson Comorbidity Index. The D'Hoore scoring system was used to identify ICD-9 codes associated with each comorbidity. Results from the IP and OT claims were combined to create overall comorbidity measures. RESULTS: The study included a total of 618,337 unique patients. The OT claims could identify almost all comorbidities (low of 88.0% for myocardial infarctions, high of 99.5% for diabetes). IP claims were much less likely to identify comorbidities (low of 11.5% for connective tissue disease, high of 45.7% for myocardial infarction). At 12 months, less than half of the beneficiaries with comorbid events during the 24-month period had been identified for dementia (43.9%), cerobrovascular disease (45.6%), peripheral vascular disease (45.6%), and myocardial infarction (48.4%). In contrast, 78.1% of patients with diabetes events and 69.0% of patients with chronic pulmonary disease events had been identified at 12 months. CONCLUSIONS: The percentage of patients ascribed comorbidities will vary significantly depending on the number of observation months. Obviously, the incidence rate for new events/diagnoses contributes to the increase over time. However, researchers must be careful since some comorbidities may not be associated with frequent enough physician office visits to accurately detect existing comorbidities when the number of observation months is short.
PMC9 DATA SCAFFOLDING: A PRAGMATIC APPROACH TO STRUCTURING A LITERATURE REVIEW SPREADSHEET TO MAXIMIZE INFORMATION, FACILITATE REVIEW AND SUPPORT ANALYSIS
Ogden K 1 , Hansen R 1 , Rattana S 2 , Neil N 1 1 ICON Clinical Research, Lifecycle Sciences Group, San Francisco, CA, USA, 2 ICON Clinical Research, Lifecycle Sciences Group, Chicago, IL, USA OBJECTIVES: Clinical literature reviews, especially systematic reviews, require the management and evaluation of large amounts of bibliographic data. Although the methodology for performing reviews is well documented, few sources share practical guidance on how to electronically manage citation data in order to efficiently inventory, organize, and assess published material. Spreadsheet tools (e.g., Excel®) give researchers unparalleled freedom to manipulate a large volume of information culled from source databases (e.g., MEDLINE®); however, many researchers lack a blueprint for structuring their data to facilitate review. METHODS: We describe a process of erecting "data scaffolding" that is critical to transforming a literature review spreadsheet into an agile, manipulable source of information that can triage, sort, and report on materials retrieved for review. RESULTS: Using a sample of literature data pulled from PubMed®, we describe several ideas for adding key structural components to a spreadsheet of citations that bring flexibility and functionality to the processes of article review and analysis. In doing so, we also describe the hows and whys of spreadsheet design to facilitate literature review, such as the importance of the spreadsheet layout; the addition of flag fields to use medical subject headings or key words to easily sort, organize, identify/retrieve, navigate, and summarize citations; and ways of leveraging built-in spreadsheet features such as autofilters, freeze-panes, and subtotals that can greatly facilitate the inventory and management of large volumes of citation data to support literature reviews. CONCLUSIONS: In an era of increasing volumes of published literature and the proliferation of rigorous, formalized, systematic and non-systematic reviews, researchers must adapt to growing demands. Existing spreadsheet tools can be leveraged to effectively meet these demands, in ways that not only provide for greater efficiency but in ways that may result in enhanced research capabilities.
PMC10 RATIONALE AND DEVELOPMENT OF AN ONLINE DIRECTORY OF DATABASE PROFILES FOR PHARMACOEPIDEMIOLOGY, OUTCOMES, AND POPULATION RESEARCH
Kamani SA, Goehring Jr EL, Singh VP, Nguyen-Khoa BA, Kapasi AJ, Jones JK DGI, Inc., Arlington, VA, USA OBJECTIVES: Large epidemiology studies using population databases are in high demand in the current health care environment. Simultaneously, the number of health care databases available for research has risen considerably. Increasingly complex research questions require population researchers to be more aware of the availability and details of databases worldwide. To address this growing need, a web-based directory with detailed profiles of population research databases was developed. (1999) (2000) (2001) (2002) (2003) . Over a 20-month period, we convened an advisory board, re-branded the website, and updated content. A web development firm built the infrastructure of bridgetodata.org. Content was developed by assessing existing database profiles and performing extensive literature reviews. A database profile template was created with 75 common fields covering the following categories: population type, demographics, physician, drug, diagnosis, procedure, economic, validation, linkage, and administrative data. We received advisory board feedback at multiple stages, and database managers were contacted for listing authorization and content approval. A quality assurance process involved systematic review of each profile by the primary editor, DGI staff, and database managers. RESULTS: The site was launched in November 2009 with 50 database profiles from USA, Europe, and Asia. It features a web interface designed to perform database searches by field type and to allow side-by-side comparison of multiple databases. Limitations included a short timeline and budgetary constraints. CONCLUSIONS: Development of a webbased directory of population research database profiles will enable the identification of appropriate databases for pharmacoepidemiologic, economic, and health services research. Other applications may include serving as an educational tool and as a model for developing new health care databases.
PMC11 CAP DATABASE-PROVISION OF OUTPATIENT PROCEDURE DATA IN A UNIFIED, STANDARDIZED LANGUAGE
Endel G, Weisser A Head Association of the Austrian Social Insurance Companies, Vienna, Austria OBJECTIVES: Due to the heterogeneous health care environment in Austria, data about procedures performed in outpatient clinics, ambulatories and in the outpatient sector have not been collected in a standardized language. However, this data is crucial for planning processes and health services provision. Therefore, the Ministry of Health in collaboration with the Austrian Social Security and 3 of 9 Federal States initiated
